CERo Therapeutics Stock (NASDAQ:CERO)

Revenue Financials Chart

Previous Close

$0.06

52W Range

$0.05 - $70.00

50D Avg

$0.23

200D Avg

$7.16

Market Cap

$66.30K

Avg Vol (3M)

$2.68M

Beta

0.30

Div Yield

-

CERO Company Profile

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

8

IPO Date

Nov 30, 2021

Website

CERO Performance

CERO Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-16.20M	$-2.93M	$-2.91M
Net Income	$-11.09M	$-2.54K	$-667.74K
EBITDA	$-16.20M	$-2.44M	$-68.58K
Basic EPS	-	$-0.39	$-0.10
Diluted EPS	-	$-0.39	$-0.10

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
LIMN	Liminatus Pharma, Inc. Class A Common Stock
OCEA	Ocean Biomedical, Inc.
XRTX	XORTX Therapeutics Inc.
GLMD	Galmed Pharmaceuticals Ltd.
BIVI	BioVie Inc.
MLEC	Moolec Science S.A.
ELAB	PMGC Holdings Inc.
PTIX	Protagenic Therapeutics, Inc.